MS
BPMC

Maven Securities’s Blueprint Medicines BPMC Stock Holding History

Maven Securities’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,000
Closed -$575K – 1176
2020
Q4 		$575K Buy
+5,000
New +$527K 0.06% 329
2020
Q1 		– Sell
-10,000
Closed -$809K – 326
2019
Q4 		$809K Buy
+10,000
New +$749K 0.07% 203
2019
Q2 		– Sell
-30,700
Closed -$2.47M – 83
2019
Q1 		$2.47M Buy
+30,700
New +$2.27M 2.19% 14
2018
Q1 		– Sell
-5,000
Closed -$388K – 69
2017
Q4 		$388K Buy
+5,000
New +$352K 0.2% 41

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Maven Securities's BPMC Position: Q1 2021 in Review

Maven Securities sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 5,000 shares — an estimated $575K sold.

Maven Securities first reported a position in BPMC in Q4 2017 and held it in 4 quarters. The position peaked at $2.47M in Q1 2019. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Maven Securities reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Maven Securities sold 5,000 Blueprint Medicines shares in Q1 2021, an estimated $575K.
  • Maven Securities first reported a position in Blueprint Medicines in Q4 2017 and held it in 4 quarters.
  • Maven Securities's Blueprint Medicines position peaked at $2.47M in Q1 2019.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.